Abstract
Background and objective
ICU-acquired weakness (ICU-AW) refers to a group of neuromuscular lesions that can develop in the ICU. It leads to decreased physical function, increased in-ICU and in-hospital mortality, and increased healthcare costs. Given its high prevalence and significant impact on patient outcomes, it is essential to have a deeper understanding of ICU-AW. In light of this, this study aimed to ascertain the prevalence, associations, and severity of ICU-AW at a tertiary hospital in the Kingdom of Saudi Arabia (KSA) and to evaluate physician awareness of this condition.
Methods
A cross-sectional study was conducted in the ICU of Al Madina General Hospital, Medina, KSA, from April 22 to August 22, 2022, involving patients who were 18 years or older and met the inclusion criteria (n=101). The overall muscle strength was assessed daily by using the Medical Research Council (MRC) scale for muscle strength. ICU-AW was identified in patients who experienced a decline in their MRC-Sum Score (MRC-SS) during their ICU stay.
Results
A total of 101 patients were enrolled in the study. The incidence of ICU-AW was 16.8% (n=17), with 23.5% exhibiting significant weakness and 76.5% having severe weakness. Post hoc comparisons showed that females had a higher incidence of ICU-AW. Fisher's exact test revealed a statistically significant relationship between ICU-AW and the longer duration of ICU stay (p=0.001), use of mechanical ventilation (p=0.034), and low hemoglobin levels (p=0.037).
Conclusions
ICU-AW was observed in 16.8% (n=17) of patients in our cohort, highlighting the significance of this condition. The study revealed a noteworthy correlation between ICU-AW and female sex, extended ICU stays, mechanical ventilation, and anemia.
Keywords: mrc-sum score (mrc-ss), medical research council (mrc) scale for muscle strength, muscle weakness, intensive care unit-acquired weakness (icu-aw), intensive care unit (icu)
Introduction
ICU-acquired weakness (ICU-AW) comprises a collection of neuromuscular impairments that can arise as a secondary complication during the treatment of other critical conditions in the ICU [1]. This condition typically manifests as symmetrical weakness in the limbs (with proximal muscles more affected than distal ones) and respiratory muscles, while facial and ocular muscles remain unaffected [2,3]. ICU-AW is most commonly caused by critical illness polyneuropathy (CIP), critical illness myopathy (CIM), or a combination of the two, known as critical illness polyneuromyopathy (CIPNM). While these conditions may present with similar clinical symptoms, their underlying pathophysiology varies. While the precise pathophysiology of ICU-AW is not fully understood, it involves complex structural and functional changes within myofibers and neurons [1]. CIP is an axonal sensorimotor polyneuropathy characterized by the loss of individual nerve fibers, whereas weakness in CIM results from the loss of thick myofilaments and subsequent myofiber death in skeletal muscle without a neurogenic etiology [4].
Muscle weakness is a common issue encountered in the ICU, with a global incidence rate ranging from 25 to 85%. Moreover, up to 36% of patients may continue to experience muscle weakness even after their discharge from the ICU [5]. Several risk factors for developing ICU-AW have been identified, including both non-modifiable and modifiable factors. Non-modifiable risk factors include prolonged critical illness, such as sepsis and inflammation, multiple organ failure, and extended periods of mechanical ventilation and ICU stay [6-10]. Modifiable risk factors include elevated blood lactate levels, hyperglycemia [10], and certain medications such as vasoactive agents, sedatives, corticosteroids, and neuromuscular blocking agents [8,10-13], as well as extended periods of bed rest and immobilization [12,14]. Additionally, women and older patients are at a higher risk of developing weakness than men and younger patients [6]. Premorbid disability and frailty may also increase the severity of weakness, while premorbid obesity is an independent protective factor against the development of ICU-AW and muscle atrophy [15].
The Medical Research Council (MRC) scale for muscle strength is currently the most widely used tool for evaluating and diagnosing ICU-AW, despite its major limitation of requiring patients to be awake and cooperative [2,16-18]. Other modalities are also being used to assess and diagnose ICU-AW. Electrophysiological assessments can be used as an alternative to the MRC scale among uncooperative patients. Ultrasonography is another option for quick and repeated bedside evaluation of muscle quantity and quality, but it may underestimate muscle and protein loss [3,19-21]. CT and MRI are more accurate and reliable in detecting muscle infiltration by adipose tissue and quantifying fat-free muscle mass, but they are expensive, require specialized staff and software, and are logistically challenging [19,21]. Additionally, CT exposes patients to a high level of radiation. Lastly, performing a nerve or muscle tissue biopsy is rare due to its invasive nature and it is not a standard procedure in routine clinical practice.
ICU-AW is associated with numerous unfavorable short- and long-term consequences, such as increased in-ICU and in-hospital mortality, prolonged mechanical ventilation and hospitalization, elevated healthcare costs, a greater likelihood of extended rehabilitation care, and decreased physical function and quality of life in the long run [1]. Given its high prevalence and significant impact on patient outcomes, it is essential to have a deeper understanding of ICU-AW. However, despite being a prevalent issue with serious implications, there is a lack of local research on its prevalence, diagnosis, risk factors, and treatment. Since there are no specific drugs or treatments available for ICU-AW, the treatment primarily focuses on nutrition and supportive therapies to alleviate symptoms. Therefore, it is crucial to investigate the pathophysiological mechanisms of ICU-AW and identify specific therapeutic drugs and strategies to improve patient outcomes [22].
Objectives
The objectives of this study were as follows: to ascertain the prevalence and severity of ICU-AW in a tertiary hospital located in Saudi Arabia, to explore various associations linked to ICU-AW, and to evaluate the level of physician awareness and recognition of this condition.
Materials and methods
Study design
This was a single-center cross-sectional study approved by the ethics committee of Taibah University and the General Directorate of Health Affairs of Medina-Ministry Of Health (MOH).
Subjects and procedures
The study included all patients who were admitted to the ICU of Al Madina General Hospital between April 22 to August 22, 2022, who were 18 years of age or older and met the inclusion criteria.
Within 48 hours of ICU admission, a total of 141 patients were consecutively screened for eligibility. Inclusion criteria consisted of patients aged 18 years or older who were admitted to the ICU (N=101). Patients who were discharged from the ICU within 48 hours, those under the age of 18 years, and those with a condition or neurological diseases severely limiting mobility were excluded from the study (n=40).
The overall muscle strength was assessed using the MRC scale for muscle strength, which is a reliable and widely used method for identifying ICU-AW in critically ill patients (Table 1) [23-25]. The MRC system evaluates muscle strength in six categories: wrist extension, elbow flexion, bilateral shoulder abduction, hip flexion, knee extension, and foot dorsiflexion. Each group is given a score from 0 to 5 based on the patient's ability to move against gravity and resistance. The total score ranges from 0 to 60, with higher scores indicating greater muscle strength. Patients who score less than 48 are identified as having significant muscle weakness, and those who score less than 36 are identified as having severe weakness. We characterized patients as having ICU-AW if their MRC-Sum Score (MRC-SS) decreased to a value below 48 at any time during their ICU stay in comparison to the initial recorded MRC-SS. Those who had an initial MRC-SS of less than 48 but did not experience a decrease during their ICU stay were characterized to have muscle weakness not related to ICU-AW. The data of the MRC-SS was obtained on the 3rd, 7th, 14th, 21st, and 28th days of admission. MRC-SS data was not obtained beyond the 28th day of the patient’s admission to the ICU.
Table 1. Medical Research Council (MRC) scale for muscle strength*.
*[26]
| Score | Interpretation |
| 0 | No contraction |
| 1 | Contraction without movement |
| 2 | Movement with gravity eliminated |
| 3 | Movement against gravity |
| 4 | Movement against resistance |
| 5 | Normal muscle force |
The researchers collected data on various sociodemographic and clinical variables, such as gender, age, duration of ICU stay, use of mechanical ventilation, medications, laboratory results, evidence of weakness, and patient comorbidities. The contents of the data collection sheet can be found in the Appendices section.
Statistical analysis
The SPSS Statistics version 26.0 (IBM Corp., Armonk, NY) was used for data analysis. Data normality was tested using the Kolmogorov-Smirnov test. Continuous data were presented as median and interquartile range (IQR), while categorical variables were represented as frequencies and percentages. Categorical variable analysis was performed using the Chi-square test, and Fisher’s exact test was used to determine if there was a significant association between ICU-AW and the sociodemographics of the sample, the duration of the ICU stay, use of mechanical ventilation, laboratory results, medications, evidence of weakness, and patient comorbidities. A p-value of less than 0.05 was considered statistically significant, and the confidence interval was set at 95%.
Ethical considerations
The study received approval from the ethics committees of Taibah University, Al Medina General Hospital, and the General Directorate of Health Affairs of Medina-Ministry Of Health (MOH). An official letter explaining the study's purpose and setting was drafted before conducting the study. Each patient participating in the study or their healthcare proxy was counseled about the study purpose and process and informed about their right to refuse participation in the study, but written consent to participate in the study was not obtained.
Results
In this study, we initially screened a total of 141 patients, of which 40 did not meet the inclusion criteria and hence were excluded. Thus, the final sample size consisted of 101 patients; Table 2 presents their sociodemographic characteristics. Of the included patients, 51.5% (n=52) were male, and 48.5% (n=49) were female, with a median age of 67 years (IQR: 23) and a median ICU stay of nine days (IQR: 11). Mechanical ventilation was required for 41.6% of the patients, and sedatives were given to 27.7%, while 60.4% of the patients received steroids, and only 5% were given paralytics. Muscle weakness was observed in 50.5% of the included patients (both ICU-AW and non-ICU-AW). Evidence of ICU-AW was found in 16.8% (N=17) of the included patients. Of those patients, 23.5% had significant weakness and 76.5% had a severe weakness.
Table 2. Prevalence of ICU-AW and sociodemographic and clinical characteristics of the sample (n=101).
IQR: interquartile Range; ICU: intensive care unit; ICU-AW: intensive care unit–acquired weakness
| Characteristics | Frequency | Percentage |
| Study sample | ||
| Inclusion | 101 | 71.6% |
| Exclusion | 40 | 28.4% |
| Gender | ||
| Male | 52 | 51.5% |
| Female | 49 | 48.5% |
| Age, years, median (IQR) | 67 (23) | |
| Duration of ICU stay, days, median (IQR) | 9 (11) | |
| Mechanical ventilation | ||
| No | 59 | 58.4% |
| Yes | 42 | 41.6% |
| Medications | ||
| Sedatives | 28 | 27.7% |
| Steroids | 61 | 60.4% |
| Paralytics | 5 | 5% |
| Evidence of weakness (ICU-AW + weakness not due to ICU-AW) | ||
| No | 50 | 49.5% |
| Yes | 51 | 50.5% |
| ICU-acquired weakness | ||
| No | 84 | 83.2% |
| Yes | 17 | 16.8% |
| Grade of ICU-AW | ||
| Significant weakness | 4 | 4.0% |
| Severe weakness | 13 | 12.9% |
Figure 1 illustrates the reasons for excluding patients from the study; the "presence of a condition or neurological diseases severely limiting mobilization" was the most common cause (90%), followed by "patients discharged from the ICU within 48 hours" (7.5%).
Figure 1. Reasons for excluding patients from the study (n=40).
ICU: intensive care unit
Figure 2 depicts the breakdown of the study sample based on the presence of comorbidities among patients. The data revealed that 58.4% of the patients had hypertension, while 56.5% had diabetes mellitus, and 45.5% had sepsis. In contrast, only 9.9% of patients suffered from acute kidney injury.
Figure 2. Distribution of sample by patient comorbidities (n=101).
COVID-19: coronavirus disease 2019
Table 3 presents the Person's Chi-squared test, which indicated a significant association between ICU-AW and patients' gender (p=0.046). Post hoc comparisons demonstrated that females had a higher incidence of ICU-AW compared to males. Additionally, Fisher's exact test revealed a statistically significant relationship between ICU-AW and the duration of ICU stay (p=0.001), with post hoc comparisons showing that patients who stayed in the ICU for 14-28 days had a higher incidence of ICU-AW than those who stayed for 7-14 days. Furthermore, there was a significant association between ICU-AW and the need for mechanical ventilation (p=0.034).
Table 3. Association between ICU-AW and sociodemographic of the sample, clinical characteristics, and patient comorbidities (n=101).
aFisher's exact test. *P-value is statistically significant
ICU: intensive care unit; ICU-AW: intensive care unit–acquired weakness
| Factors | Categories | ICU-AW | P-value | |
| No | Yes | |||
| Sex | Male | 47 (56%) | 5 (29.4%) | 0.046* |
| Female | 37 (44%) | 12 (70.6%) | ||
| Agea | Less than 40 years | 11 (13.1%) | 3 (17.6%) | 0.710 |
| 40-50 years | 8 (9.5%) | 0 (0%) | ||
| 51-60 years | 13 (15.5%) | 3 (17.6%) | ||
| More than 60 years | 52 (61.9%) | 11 (64.7%) | ||
| Duration of ICU stay (days)a | Less than 7 days | 33 (39.3%) | 0 (0%) | 0.001* |
| 7-14 days | 31 (36.9%) | 7 (41.2%) | ||
| 14-28 days | 20 (23.8%) | 10 (58.8%) | ||
| Mechanical ventilation | No | 53 (63.1%) | 6 (35.3%) | 0.034* |
| Yes | 31 (36.9%) | 11 (64.7%) | ||
| Diabetes mellitus | No | 45 (53.6%) | 9 (52.9%) | 0.962 |
| Yes | 39 (46.4%) | 8 (47.1%) | ||
| Hypertension | No | 35 (41.7%) | 7 (41.2%) | 0.970 |
| Yes | 49 (58.3%) | 10 (58.8%) | ||
| Acute kidney injurya | No | 75 (89.3%) | 16 (94.1%) | 0.469 |
| Yes | 9 (10.7%) | 1 (5.9%) | ||
| Chronic kidney diseasea | No | 73(86.9%) | 14 (82.4%) | 0.700 |
| Yes | 11 (13.1%) | 3 (17.6%) | ||
| Covid-19a | No | 71 (84.5%) | 15 (88.2%) | .517 |
| Yes | 13 (15.5%) | 2 (11.8%) | ||
| Sepsis | No | 46 (54.8%) | 9 (52.9%) | 0.891 |
| Yes | 38 (45.2%) | 8 (47.1%) | ||
| Sedatives | No | 62 (73.8%) | 11 (64.7%) | 0.553 |
| Yes | 22 (26.2%) | 6 (35.3%) | ||
| Steroids | No | 33 (39.3%) | 7 (41.2%) | 0.884 |
| Yes | 51 (60.7%) | 10 (58.8%) | ||
| Paralyticsa | No | 80 (95.2%) | 16 (94.1%) | 0.610 |
| Yes | 4 (4.8%) | 1 (5.9%) | ||
As presented in Table 4, Fisher's exact test showed that there was a statistically significant association between ICU-AW and hemoglobin levels in the blood (p=0.037). Post hoc comparisons revealed that patients who had anemia had a higher rate of ICU-AW compared to patients whose hemoglobin was in the normal range.
Table 4. Association between ICU-AW and various laboratory tests (n=101).
aFisher's exact test. *P-value is statistically significant
ICU: intensive care unit; ICU-AW: intensive care unit–acquired weakness
| Laboratory tests | Categories | ICU-AW, n (%) | P-value | |
| No | Yes | |||
| Hemoglobina | Normal | 18 (21.4%) | 0 (0%) | 0.037* |
| Anemia | 66 (78.6%) | 17 (100%) | ||
| Platelets | Normal | 65 (77.4%) | 11 (64.7%) | 0.269 |
| Thrombocytopenia | 19 (22.6%) | 6 (35.3%) | ||
| Lactate | Normal | 62 (73.8%) | 10 (58.8%) | 0.213 |
| High lactate | 22 (26.2%) | 7 (41.2%) | ||
| Creatinine kinasea | Normal | 73 (86.9%) | 17 (100%) | 0.203 |
| High creatinine kinase level | 11 (13.1%) | 0 (0%) | ||
| Glucose | Normal | 35 (41.7%) | 7 (41.2%) | 0.984 |
| Hyperglycemia | 23 (27.4%) | 5 (29.4%) | ||
| Uncontrolled hyperglycemia | 26 (31%) | 5 (29.4%) | ||
| Albumina | Normal | 38 (45.2%) | 4 (23.5%) | 0.113 |
| Hypoalbuminemia | 46 (54.8%) | 13 (76.5%) | ||
| Calcium | Normal | 33 (39.3%) | 8 (47.1%) | 0.552 |
| Hypocalcemia | 51 (60.7%) | 9 (52.9%) | ||
| Potassium | Normal | 63 (75%) | 12 (70.6%) | 0.704 |
| Hypokalemia | 21 (25%) | 5 (29.4%) | ||
A comprehensive review of the medical charts revealed that none of the patients identified with ICU-AW in our study had received a formal diagnosis of the condition from the treating team, as evidenced by the absence of any mention of ICU-AW in the medical charts.
Discussion
In this cross-sectional study, we observed that the prevalence of ICU-AW was 16.8% (n=17), with 76.5% of cases classified as severe ICU-AW. Previous studies have reported a broad range in terms of ICU-AW prevalence (25-85%), which can be attributed to the lack of universal consensus regarding its definition and the varied tools employed to assess ICU-AW. We defined ICU-AW if the patient met the following two criteria: a decrease in MRC-SS from the initial recorded MRC-SS and a decline in MRC-SS to a value of less than 48. This likely led to a more precise detection of ICU-AW but also to a lower prevalence of the disease. Furthermore, muscle weakness was identified in approximately half of the patients included in the study (50.5%), encompassing both those diagnosed with ICU-AW and those exhibiting muscle weakness that did not meet the criteria mentioned above.
Other findings of the study revealed a statistically significant correlation between ICU-AW and female sex, extended ICU stay, use of mechanical ventilation, and anemia. The correlation between ICU-AW and ICU length of stay and use of mechanical ventilation is consistent with findings of other studies conducted in KSA and China [27,28]. However, the study by Asfour found no difference in ICU-AW between males and females [27].
This study showed no significant difference in the incidence of ICU-AW and the following comorbidities and lab values: COVID-19, sepsis, diabetes mellitus, hypertension, chronic kidney disease, acute kidney injury, and albumin level. This is in contrast to many studies that found that COVID-19 infection is associated with a significantly higher incidence of ICU-AW [29-31]. Furthermore, Yang et al. [10] conducted a systemic review and meta-analysis of 14 studies that aimed to determine the risk factors for ICU-AW. The results showed that both Systemic Inflammatory Response Syndrome (SIRS) and sepsis were independent risk factors for ICU-AW, especially if they lasted for a long duration of time.
Our study did not show a significant association between ICU-AW and the use of sedatives, neuromuscular blocking agents (NMBAs), or corticosteroids; this contrasts with other studies that suggest an association between medications commonly used in ICU and ICU-AW. Latronico et al. found that immobility caused by prolonged sedation increases the risk of ICU-AW [2]. A study by Qin et al. has shown that prolonged corticosteroid use can result in steroid myopathies and may contribute to ICU-AW by suppressing muscle protein synthesis, which causes muscle wasting [32]. Furthermore, a meta-analysis of systemic corticosteroid administration and ICU-AW concluded that corticosteroid use was a significant risk factor for developing ICU-AW and that reducing corticosteroids would help lower ICU-AW [33]. Yang et al. found that NMBAs will cause adverse muscle effects that increase the probability of muscle atrophy and exacerbate ventilator-induced diaphragmatic weakness [10].
Of note, although our study revealed an ICU-AW prevalence of 16.8% (N=17) among patients, none of them had an officially documented diagnosis of the condition in their medical charts as confirmed by the treating team. This finding highlights a significant gap in patient management, with a lack of proactive measures to prevent or address this condition.
Our study has some limitations, which include its cross-sectional design, the fact that it excluded a large number of patients, its single-center design, and its limited sample size. The study used the MRC scale for muscle strength to assess ICU-AW, which is currently the most widely used and reliable tool for evaluating and diagnosing ICU-AW, despite its major limitations [2,16-18].
Conclusions
The prevalence of ICU-AW in this study was 16.8% (n=17) while muscle weakness either due to ICU-AW or non-ICU-AW was found in 50.5% of the study population. However, none of these patients had an officially documented diagnosis of the condition in their medical charts prepared by the treating team. This finding highlights a significant gap in patient management, with a lack of proactive measures taken to prevent or address this condition. The study also revealed a noteworthy correlation between ICU-AW and female sex, extended ICU stays, mechanical ventilation, and anemia.
Acknowledgments
Primarily, we thank God for getting us through all the difficulties. Also, we would like to offer our appreciation to Taibah University, with special regard to the Faculty of Medicine, for providing us with the chance to conduct this original research. In addition, we would like to express our sincere thanks to our supervisor for his guidance and support throughout the course of the project. Also, we would like to extend our gratitude to the nursing staff in the intensive care unit of Al Madina General Hospital for their valuable efforts and cooperation.
Appendices
Data collection sheet
A Cross-Sectional Study on the Impact of ICU-Acquired Weakness: Prevalence, Associations and Severity
Participant number: ……………………. Date: ……/……/……
This is a data collection form for the “A Cross-Sectional Study on the Impact of ICU-Acquired Weakness: Prevalence, Associations and Severity “. To be filled by the study investigators and team.
Patient eligibility
In order for the subject to be eligible for the study, he/she must meet ALL inclusion criteria and none of the exclusion criteria. If the response is “No” to any of the inclusion criteria, the subject is not eligible to participate in the study.
Inclusion criteria
All male and female patients aged 18 years and older who were admitted to the ICU at the time of signing the consent form:
□ Yes □ No
Exclusion criteria
1. Patients discharged from the ICU within 48 hours:
□ Yes □ No
2. Age under 18 years:
□ Yes □ No
3. Presence of a condition or neurological disease severely limiting mobilization:
□ Yes □ No
A. Baseline demographic data
1. Patient name: ……………………………………
2. File number: …………………………………….
3. Gender: □ Male □ Female
4. Age: ……………years
5. Diagnosis: ……………………………………….
B. Comorbidities
o Diabetes.
o Hypertension.
o Acute kidney injury.
o Chronic kidney disease.
o Covid-19.
o Sepsis.
o Others: …………………………………………
o None.
C. Duration of ICU stay
Number of days ………….
D. Application of assisted mechanical ventilation
□ Yes □ No
□ Date of intubation: / /
□ Date of extubation: / /
□ Duration of mechanical ventilation: ……………
Table 5. MRC score results.
| Day of MRC score | 0 | 1 | 2 | 3 | 4 | 5 |
| ICU Admission (Day1) Date: / /2022 | ||||||
| Day (2) Date: / /2022 | ||||||
| Day (3) Date: / /2022 | ||||||
| Day (4) Date: / /2022 | ||||||
| Day (5) Date: / /2022 | ||||||
| Day (6) Date: / /2022 | ||||||
| Day (7) Date: / /2022 | ||||||
| Day (8) Date: / /2022 | ||||||
| Day (9) Date: / /2022 | ||||||
| Day (10) Date: / /2022 | ||||||
| Day (11) Date: / /2022 | ||||||
| Day (12) Date: / /2022 | ||||||
| Day (13) Date: / /2022 | ||||||
| Day (14) Date: / /2022 | ||||||
| Day (15) Date: / /2022 | ||||||
| Day (16) Date: / /2022 | ||||||
| Day (17) Date: / /2022 | ||||||
| Day (18) Date: / /2022 | ||||||
| Day (19) Date: / /2022 | ||||||
| Day (20) Date: / /2022 | ||||||
| Day (21) Date: / /2022 | ||||||
| Day (22) Date: / /2022 | ||||||
| Day (23) Date: / /2022 | ||||||
| Day (24) Date: / /2022 | ||||||
| Day (25) Date: / /2022 | ||||||
| Day (26) Date: / /2022 | ||||||
| Day (27) Date: / /2022 | ||||||
| Day (28) Date: / /2022 |
Table 6. Medication regimen.
| Day of medicine administration | Sedative | Steroids | Paralytics |
| Day (1) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (2) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (3) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (4) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (5) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (6) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (7) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (8) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (9) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (10) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (11) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (12) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (13) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (14) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (15) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (16) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (17) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (18) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (19) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (20) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (21) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (22) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (23) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (24) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (25) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (26) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (27) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
| Day (28) | □ Yes □ No | □ Yes □ No | □ Yes □ No |
Table 7. Baseline laboratory investigations.
| Laboratory tests | Result |
| Hemoglobin | |
| Platelets | |
| Lactate | |
| Creatinine kinase CK | |
| Blood glucose | |
| Albumin | |
| Calcium Ca | |
| Potassium K |
Data collector Investigator agreement
(PI/co-PI/designee)
Name: …………………………… Name: ………………………………………
I.D: ……………………………… I.D:………………………………………….
Position: ………………………… Position: ……………………………………
Signature: ………………….…… Signature: …………………………………..
Date: ……………………………. Date: ………………………………………
The authors have declared that no competing interests exist.
Author Contributions
Concept and design: Ruba A. Alamri, Anas Khalil, Ghaida H. Aljabri, Elham A. Shahat, Rahaf I. Almughamsi, Walaa A. Almeshhen
Acquisition, analysis, or interpretation of data: Ruba A. Alamri, Anas Khalil, Ghaida H. Aljabri, Elham A. Shahat, Rahaf I. Almughamsi, Walaa A. Almeshhen
Drafting of the manuscript: Ruba A. Alamri, Anas Khalil, Ghaida H. Aljabri, Elham A. Shahat, Rahaf I. Almughamsi, Walaa A. Almeshhen
Critical review of the manuscript for important intellectual content: Ruba A. Alamri, Anas Khalil, Ghaida H. Aljabri, Elham A. Shahat, Rahaf I. Almughamsi, Walaa A. Almeshhen
Supervision: Anas Khalil
Human Ethics
Consent was obtained or waived by all participants in this study. IRB of the General Directorate of Health Affairs in Madinah issued approval NCBE-KACST, KSA: (H-03-M-84); 019-22
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.ICU-acquired weakness. Vanhorebeek I, Latronico N, Van den Berghe G. Intensive Care Med. 2020;46:637–653. doi: 10.1007/s00134-020-05944-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.The ICM research agenda on intensive care unit-acquired weakness. Latronico N, Herridge M, Hopkins RO, et al. Intensive Care Med. 2017;43:1270–1281. doi: 10.1007/s00134-017-4757-5. [DOI] [PubMed] [Google Scholar]
- 3.Intensive care unit-acquired weakness: unanswered questions and targets for future research. Piva S, Fagoni N, Latronico N. F1000Res. 2019;8:4–6. doi: 10.12688/f1000research.17376.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Latronico N, Bolton CF. Lancet Neurol. 2011;10:931–941. doi: 10.1016/S1474-4422(11)70178-8. [DOI] [PubMed] [Google Scholar]
- 5.Intensive care unit-acquired weakness. Griffiths RD, Hall JB. Crit Care Med. 2010;38:779–787. doi: 10.1097/CCM.0b013e3181cc4b53. [DOI] [PubMed] [Google Scholar]
- 6.Paresis acquired in the intensive care unit: a prospective multicenter study. De Jonghe B, Sharshar T, Lefaucheur JP, et al. JAMA. 2002;288:2859–2867. doi: 10.1001/jama.288.22.2859. [DOI] [PubMed] [Google Scholar]
- 7.Critical illness polyneuropathy and myopathy 20 years later. No man's land? No, it is our land! Latronico N. Intensive Care Med. 2016;42:1790–1793. doi: 10.1007/s00134-016-4475-4. [DOI] [PubMed] [Google Scholar]
- 8.Impact of vasoactive medications on ICU-acquired weakness in mechanically ventilated patients. Wolfe KS, Patel BK, MacKenzie EL, et al. Chest. 2018;154:781–787. doi: 10.1016/j.chest.2018.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Fan E, Cheek F, Chlan L, et al. Am J Respir Crit Care Med. 2014;190:1437–1446. doi: 10.1164/rccm.201411-2011ST. [DOI] [PubMed] [Google Scholar]
- 10.Risk factors for intensive care unit-acquired weakness: a systematic review and meta-analysis. Yang T, Li Z, Jiang L, Wang Y, Xi X. Acta Neurol Scand. 2018;138:104–114. doi: 10.1111/ane.12964. [DOI] [PubMed] [Google Scholar]
- 11.Aminoglycoside use and intensive care unit-acquired weakness: a systematic review and meta-analysis. Yang T, Li ZQ, Li HL, Zhou JX, Chen GQ. PLoS One. 2020;15:0. doi: 10.1371/journal.pone.0230181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Complications of sedation in critical illness: an update. Foster J. Crit Care Nurs Clin North Am. 2016;28:227–239. doi: 10.1016/j.cnc.2016.02.003. [DOI] [PubMed] [Google Scholar]
- 13.Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis. Yang T, Li Z, Jiang L, Xi X. Crit Care. 2018;22:187. doi: 10.1186/s13054-018-2111-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.The impact of extended bed rest on the musculoskeletal system in the critical care environment. Parry SM, Puthucheary ZA. Extrem Physiol Med. 2015;4:16–18. doi: 10.1186/s13728-015-0036-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness. Goossens C, Marques MB, Derde S, et al. J Cachexia Sarcopenia Muscle. 2017;8:89–101. doi: 10.1002/jcsm.12131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Assessment of limb muscle strength in critically ill patients: a systematic review. Vanpee G, Hermans G, Segers J, Gosselink R. Crit Care Med. 2014;42:701–711. doi: 10.1097/CCM.0000000000000030. [DOI] [PubMed] [Google Scholar]
- 17.What is the diagnostic accuracy of single nerve conduction studies and muscle ultrasound to identify critical illness polyneuromyopathy: a prospective cohort study. Kelmenson DA, Quan D, Moss M. Crit Care. 2018;22:342. doi: 10.1186/s13054-018-2281-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.A framework for diagnosing and classifying intensive care unit-acquired weakness. Stevens RD, Marshall SA, Cornblath DR, et al. Crit Care Med. 2009;37:0–308. doi: 10.1097/CCM.0b013e3181b6ef67. [DOI] [PubMed] [Google Scholar]
- 19.Clinical review: peripheral muscular ultrasound in the ICU. Formenti P, Umbrello M, Coppola S, Froio S, Chiumello D. https://doi.org/10.1186/s13613-019-0531-x. Ann Intensive Care. 2019;9:57. doi: 10.1186/s13613-019-0531-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Assessment of muscle wasting in long-stay ICU patients using a new ultrasound protocol. Hernández-Socorro CR, Saavedra P, López-Fernández JC, Ruiz-Santana S. Nutrients. 2018;10:24–28. doi: 10.3390/nu10121849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Critical evaluation of muscle mass loss as a prognostic marker of morbidity in critically ill patients and methods for its determination. Joskova V, Patkova A, Havel E, et al. J Rehabil Med. 2018;50:696–704. doi: 10.2340/16501977-2368. [DOI] [PubMed] [Google Scholar]
- 22.Intensive care unit-acquired weakness: a review of recent progress with a look toward the future. Wang W, Xu C, Ma X, Zhang X, Xie P. Front Med (Lausanne) 2020;7:559789. doi: 10.3389/fmed.2020.559789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Compston A. Brain. 2010;133:2838–2844. doi: 10.1093/brain/awq270. [DOI] [PubMed] [Google Scholar]
- 24.Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Kleyweg RP, van der Meché FG, Schmitz PI. Muscle Nerve. 1991;14:1103–1109. doi: 10.1002/mus.880141111. [DOI] [PubMed] [Google Scholar]
- 25.Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Florence JM, Pandya S, King WM, et al. Phys Ther. 1992;72:115–122. doi: 10.1093/ptj/72.2.115. [DOI] [PubMed] [Google Scholar]
- 26.A new two-tier strength assessment approach to the diagnosis of weakness in intensive care: an observational study. Parry SM, Berney S, Granger CL, et al. Crit Care. 2015;19:52. doi: 10.1186/s13054-015-0780-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Contributing factors for acquired muscle weakness in intensive care unit. Asfour HI. J Nurs Educ Pract. 2016;6:2–5. [Google Scholar]
- 28.Early incidence and prognosis of ICU-acquired weakness in mechanical ventilation patients (Article in Chinese) Qiu Y, Jiang L, Xi X. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31:821–826. doi: 10.3760/cma.j.issn.2095-4352.2019.07.005. [DOI] [PubMed] [Google Scholar]
- 29.Muscle strength/intensive care unit acquired weakness in COVID-19 and non-COVID-19 patients. Rahiminezhad E, Zakeri MA, Dehghan M. Nurs Crit Care. 2023;28:1012–1021. doi: 10.1111/nicc.12830. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Intensive care unit acquired muscle weakness in COVID-19 patients. Van Aerde N, Van den Berghe G, Wilmer A, Gosselink R, Hermans G. Intensive Care Med. 2020;46:2083–2085. doi: 10.1007/s00134-020-06244-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Muscle strength and physical performance in patients without previous disabilities recovering from COVID-19 pneumonia. Paneroni M, Simonelli C, Saleri M, et al. Am J Phys Med Rehabil. 2021;100:105–109. doi: 10.1097/PHM.0000000000001641. [DOI] [PubMed] [Google Scholar]
- 32.Effects of corticosteroids in the development of limb muscle weakness in a porcine intensive care unit model. Aare S, Radell P, Eriksson LI, Akkad H, Chen YW, Hoffman EP, Larsson L. Physiol Genomics. 2013;45:312–320. doi: 10.1152/physiolgenomics.00123.2012. [DOI] [PubMed] [Google Scholar]
- 33.Intensive care unit-acquired weakness and the COVID-19 pandemic: a clinical review. Qin ES, Hough CL, Andrews J, Bunnell AE. PM R. 2022;14:227–238. doi: 10.1002/pmrj.12757. [DOI] [PubMed] [Google Scholar]